Celldex (CLDX) Commences Rindopepimut w/ Avastin Phase 2
Up)
Celldex Therapeutics, Inc. (Nasdaq: CLDX) reports that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the “ReACT Study.” This new study will run in parallel with Celldex’s Phase 3 trial (ACT IV) evaluating rindopepimut in patients with newly diagnosed EGFRvIII-expressing glioblastoma (GB).
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
- Pre-Open Movers 5/24: (P) (HPQ) (PVH) Higher; (NTAP) (MTGE) (TIF) Lower (more...)
- After-Hours Movers 05/23: (P) (HPQ) (PVH) Higher; (MNOV) (NTAP) (CLDX) Lower
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
